Search Within

Philip Wayne Kantoff

Formats
  1. Journal Article (118)
  2. Meeting Abstract (71)
  3. Review (4)
  4. Correspondence (2)
  5. Editorial (2)
  6. Research Letter (1)
Groups
  1. Department of Medicine (198)
  2. Genitourinary Oncology Service (198)
  3. Solid Tumor Oncology Division (198)
  4. Sloan Kettering Institute Postdocs (71)
  5. GSK Faculty (26)
  6. Human Oncology and Pathogenesis Program (23)

More Groups

People
  1. Konrad Stopsack (44)
  2. Goutam Chakraborty (29)
  3. Ying Mazzu (29)
  4. Subhiksha Nandakumar (27)
  5. Michael Morris (26)
  6. Yuki Yoshikawa (23)

More People

Years
  1. 2025 (4)
  2. 2024 (6)
  3. 2023 (3)
  4. 2022 (14)
  5. 2021 (19)
  6. 2020 (34)

More Years

Publications
  1. Journal of Clinical Oncology (57)
  2. Clinical Cancer Research (17)
  3. Cancer Research (16)
  4. Cancer (9)
  5. Cancer Epidemiology Biomarkers and Prevention (8)
  6. European Urology (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (62)
  2. American Association for Cancer Research (46)
  3. Nature Publishing Group (16)
  4. Oxford University Press (11)
  5. Wiley Blackwell (11)
  6. Elsevier Science, Inc. (8)

More Publishers

Results (198)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases
    Journal Article

    McKay, R.; Haider, B.; Duh, M. S.; Valderrama, A.; Nakabayashi, M.; Fiorillo, M.; Ristovska, L.; Wen, L.; Kantoff, P.
    Prostate Cancer and Prostatic Diseases (2017)

    Fulltext@MSK | Save
  • ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis
    Journal Article

    Bose, R.; Karthaus, W. R.; Armenia, J.; Abida, W.; Iaquinta, P. J.; Zhang, Z.; Wongvipat, J.; Wasmuth, E. V.; Shah, N.; Sullivan, P. S.; more...
    Nature (2017)

    Fulltext@MSK | Save
  • The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer
    Journal Article

    Patel, S. A.; Chen, M. H.; Loffredo, M.; Renshaw, A.; Kantoff, P. W.; D'Amico, A. V.
    Prostate Cancer and Prostatic Diseases (2017)

    Fulltext@MSK | Save
  • Surrogate end points for all-cause mortality in men with localized unfavorable-risk prostate cancer treated with radiation therapy vs radiation therapy plus androgen deprivation therapy: A secondary analysis of a randomized clinical trial
    Journal Article

    Royce, T. J.; Chen, M. H.; Wu, J.; Loffredo, M.; Renshaw, A. A.; Kantoff, P. W.; D'Amico, A. V.
    JAMA Oncology (2017)

    Fulltext@MSK | Save
  • Neoadjuvant enzalutamide prior to prostatectomy
    Journal Article

    Montgomery, B.; Tretiakova, M. S.; Joshua, A. M.; Gleave, M. E.; Fleshner, N.; Bubley, G. J.; Mostaghel, E. A.; Chi, K. N.; Lin, D. W.; Sanda, M.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death
    Journal Article

    Sanford, N. N.; Chen, M. H.; Loffredo, M.; Renshaw, A.; Kantoff, P. W.; D'Amico, A. V.
    Prostate Cancer and Prostatic Diseases (2017)

    Fulltext@MSK | Save
  • Cancer nanomedicine: Progress, challenges and opportunities
    Journal Article

    Shi, J.; Kantoff, P. W.; Wooster, R.; Farokhzad, O. C.
    Nature Reviews Cancer (2017)

    Fulltext@MSK | Save
  • A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer
    Journal Article

    McKay, R. R.; Werner, L.; Mostaghel, E. A.; Lis, R.; Voznesensky, O.; Zhang, Z.; Marck, B. T.; Matsumoto, A. M.; Domachevsky, L.; Zukotynski, K. A.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer
    Journal Article

    Qu, F.; Xie, W.; Nakabayashi, M.; Zhang, H.; Jeong, S. H.; Wang, X.; Komura, K.; Sweeney, C. J.; Sartor, O.; Lee, G. S. M.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Revised overall survival analysis of a phase II, randomized, double-blind, controlled study of PROSTVAC in men with metastatic castration-resistant prostate cancer
    Journal Article

    Kantoff, P. W.; Gulley, J. L.; Pico-Navarro, C.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save